Goncalves MD, Farooki A. Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia. Integr Cancer Ther. 2022;21:15347354211073163. doi:10.1177/15347354211073163

Tankova T, et al. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers. 2022; 14(7):1598. https://doi.org/10.3390/cancers14071598

Shen S et al. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer. Cancer. 2023; 129(24): 3854-3861. doi:10.1002/cncr.34928

Pla Peris B et al. Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations. Front Endocrinol (Lausanne). 2022;13:802612. Published 2022 Jan 31. doi:10.3389/fendo.2022.802612

Rugo HS et al. A multidisciplinary approach to optimizing care of patients treated with alpelisib. Breast. 2022;61:156-167. doi:10.1016/j.breast.2021.12.016

Sriravindrarajah A et al. Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibition. Endocrinol Diabetes Metab Case Rep. 2024;2024(4):24-0040. Published 2024 Oct 21. doi:10.1530/EDM-24-0040

Simanshu DK, et al. BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction. Science. 2025 Jul 24;389(6758):409-415. doi: 10.1126/science.adq2004. Epub 2025 Jun 12. PMID: 40504949.

Buckbinder L et al. STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts. Cancer Discov. 2023 Nov 1;13(11):2432-2447. doi: 10.1158/2159-8290.CD-23-0396. PMID: 37623743; PMCID: PMC10618743.

Juric, Dejan & Giordano et al. Abstract PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients. Clinical Cancer Research. 31. PS7-02. 10.1158/1557-3265.SABCS24-PS7-02.

Jia, W.; Cheng, X. In Silico Discovery of a Novel Potential Allosteric PI3Kα Inhibitor Incorporating 3-(2-Chloro-5-fluorophenyl)isoindolin-1-one to Target Head and Neck Squamous Cell Carcinoma. Biology 2025, 14, 896. https://doi.org/10.3390/biology14070896

Hanker AB et al. Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. Cancer Discov. 2019;9(4):482-491. doi:10.1158/2159-8290.CD-18-1175

Moore H et al. Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care. Clinical Breast Cancer Volume 25, Issue 1, January 2025, Pages 1-11

Liu D. et al., Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. Cancer Medicine, Volume11, Issue8, April 2022, Pages 1796-1804